论文部分内容阅读
目的评价坦索罗辛联合溴吡斯的明治疗前列腺增生伴尿潴留的临床效果。方法收集2013年1月~2016年12月以上四家医院前列腺增生伴尿潴留患者60例,进行为期6周的治疗。随机分成A、B两组,A组(n=30)单用坦索罗辛(0.2 mg,每晚),B组(n=30)联合服用坦索罗辛(0.2 mg,每晚)和溴吡斯的明(60 mg,3次/d),两组患者均留置尿管1周。两组分别在治疗前后以国际前列腺症状评分(IPSS)、生活质量评估(QOL)、膀胱过度活动症评分(OABSS)、最大尿流率(Qmax)以及残余尿量(RV)为评估指标,比较两组治疗前后的上述指标以及治疗效果。结果治疗6周后,可评价病例52例,A组25例,B组27例;与治疗前比较,两组治疗后的IPSS评分、QOL评分、Qmax、RV均得到显著改善(P<0.01);A组治疗前后的OABSS评分差异有统计学意义(P<0.05),B组治疗前后的OABSS评分差异有统计学意义(P<0.01)。B组治疗后的IPSS评分、Qmax、RV明显优于A组(P<0.05),而两组治疗后的QOL、OABSS评分比较差异无统计学意义(P>0.05)。结论坦索罗辛联合溴吡斯的明比单用坦索罗辛更能有效地治疗前列腺增生引起的尿潴留,并不明显增加患者膀胱过度活动症状,具有较好临床运用价值。
Objective To evaluate the clinical effect of tamsulosin combined with tribromide in treating benign prostatic hyperplasia with urinary retention. Methods Sixty patients with benign prostatic hyperplasia and urinary retention in the four hospitals from January 2013 to December 2016 were collected and treated for 6 weeks. Patients were randomly assigned to receive either tamsulosin (0.2 mg per night) in group A (n = 30), tamsulosin (0.2 mg per night) in group B (n = 30) Brombestigmine (60 mg, 3 times / d), two groups of patients were catheterized for 1 week. The scores of IPSS, QOL, OABSS, Qmax and residual urine before and after treatment were compared between the two groups The two groups before and after treatment of the above indicators and treatment. Results After 6 weeks of treatment, 52 cases could be evaluated, 25 cases in group A and 27 cases in group B. IPSS score, QOL score, Qmax and RV were significantly improved after treatment (P <0.01) ; The OABSS scores of A group before and after treatment were significantly different (P <0.05). The OABSS scores of B group before and after treatment were significantly different (P <0.01). The scores of IPSS, Qmax and RV in group B were significantly better than those in group A (P <0.05). There was no significant difference in QOL and OABSS between the two groups after treatment (P> 0.05). Conclusion Tamsulosin combined with triamcinolone acetonide is more effective than tamsulosin alone in the treatment of urinary retention induced by benign prostatic hyperplasia. It does not significantly increase the overactive bladder symptoms and has good clinical value.